MCID: END084
MIFTS: 44

Endocrine System Disease

Categories: Endocrine diseases, Immune diseases

Aliases & Classifications for Endocrine System Disease

MalaCards integrated aliases for Endocrine System Disease:

Name: Endocrine System Disease 12 15 17
Abnormality of the Endocrine System 29
Disorder of Endocrine System 29
Endocrine System Diseases 43

Classifications:



External Ids:

Disease Ontology 12 DOID:28
ICD9CM 34 259.9
MeSH 43 D004700
NCIt 49 C3009
SNOMED-CT 67 67432001
ICD10 32 E34.9
UMLS 71 C0014130

Summaries for Endocrine System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body.

MalaCards based summary : Endocrine System Disease, also known as abnormality of the endocrine system, is related to pancreas disease and gonadal disease, and has symptoms including cushingoid facies, pathological conditions, signs and symptoms and breast pain male. An important gene associated with Endocrine System Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and Cell Differentiation - Index. The drugs Insulin glargine and Insulin aspart have been mentioned in the context of this disorder. Affiliated tissues include endocrine glands which secretes a type of hormone directly into the bloodstream to regulate the body, bone and testes.

Related Diseases for Endocrine System Disease

Diseases in the Endocrine System Disease family:

Autoimmune Disease of Endocrine System

Diseases related to Endocrine System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 234)
# Related Disease Score Top Affiliating Genes
1 pancreas disease 33.2 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
2 gonadal disease 33.2 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
3 thyroid gland disease 33.1 MIR9-1 MIR30A MIR221 MIR21 MIR199A1 MIR196A1
4 alopecia, neurologic defects, and endocrinopathy syndrome 11.3
5 precocious puberty, male-limited 11.1
6 cortisone reductase deficiency 11.1
7 parathyroid gland disease 11.1
8 pituitary gland disease 11.1
9 adrenal gland disease 11.1
10 nervous system cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR214
11 nervous system disease 11.0 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR214
12 stomach disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
13 hematologic cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
14 gastrointestinal system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
15 lung cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
16 intestinal disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
17 thoracic cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
18 gastrointestinal system cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
19 endocrine gland cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
20 respiratory system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
21 cell type cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
22 respiratory system cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
23 hepatocellular carcinoma 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
24 leukocyte disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR214
25 reproductive system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
26 connective tissue disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
27 large intestine cancer 11.0 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
28 central nervous system disease 11.0 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR214
29 overnutrition 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR21 MIR199A1
30 squamous cell carcinoma, head and neck 11.0 MIR9-1 MIR483 MIR30A MIR221 MIR214 MIR21
31 uterine anomalies 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
32 leukemia, acute myeloid 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
33 female reproductive system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
34 eye disease 11.0 SERPINA3 MIR9-1 MIR483 MIR30A MIR214 MIR21
35 body mass index quantitative trait locus 11 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR21 MIR199A1
36 lymphoma, non-hodgkin, familial 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR214
37 urinary system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
38 immune system disease 11.0 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR21
39 male reproductive system disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
40 prostate disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
41 male reproductive organ cancer 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
42 acquired metabolic disease 11.0 SERPINA3 MIR9-1 MIR483 MIR30A MIR214 MIR21
43 arteries, anomalies of 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR221
44 cervix disease 11.0 SERPINA3 MIR9-1 MIR483 MIR34A MIR30A MIR214
45 glucose metabolism disease 11.0 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
46 leukemia, chronic lymphocytic 11.0 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
47 upper respiratory tract disease 11.0 SERPINA3 MIR9-1 MIR483 MIR30A MIR21 MIR199A1
48 colonic disease 11.0 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
49 autosomal genetic disease 11.0 SERPINA3 MIR9-1 MIR483 MIR214 MIR21 MIR199A1
50 breast disease 11.0 SERPINA3 MIR9-1 MIR34A MIR30A MIR221 MIR21

Graphical network of the top 20 diseases related to Endocrine System Disease:



Diseases related to Endocrine System Disease

Symptoms & Phenotypes for Endocrine System Disease

UMLS symptoms related to Endocrine System Disease:


cushingoid facies, pathological conditions, signs and symptoms, breast pain male

Drugs & Therapeutics for Endocrine System Disease

Drugs for Endocrine System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Insulin glargine Approved Phase 4 160337-95-1
2
Insulin aspart Approved Phase 4 116094-23-6 16132418
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Norepinephrine Approved Phase 4 51-41-2 439260
8
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11 Insulin, Long-Acting Phase 4
12 Insulin degludec, insulin aspart drug combination Phase 4
13 Psychotropic Drugs Phase 4
14 Antidepressive Agents Phase 4
15 Hormone Antagonists Phase 4
16 Hormones Phase 4
17 Gastrointestinal Agents Phase 4
18 Antineoplastic Agents, Hormonal Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Hydrocortisone hemisuccinate Phase 4
21 Hydrocortisone 17-butyrate 21-propionate Phase 4
22 Antimetabolites Phase 4
23 HIV Protease Inhibitors Phase 4
24
protease inhibitors Phase 4
25 Neurotransmitter Agents Phase 4
26 Sympathomimetics Phase 4
27 Adrenergic Agonists Phase 4
28 Epinephryl borate Phase 4
29 Vasoconstrictor Agents Phase 4
30 Autonomic Agents Phase 4
31 Adrenergic Agents Phase 4
32 glucocorticoids Phase 4
33 Antiemetics Phase 4
34 Serotonin Uptake Inhibitors Phase 4
35 BB 1101 Phase 4
36 Serotonin Agents Phase 4
37 Serotonin Receptor Agonists Phase 4
38 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
39 Hypoglycemic Agents Phase 4
40 Sodium-Glucose Transporter 2 Inhibitors Phase 4
41 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
42
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
43
Metformin Approved Phase 3 657-24-9 14219 4091
44
Glimepiride Approved Phase 3 93479-97-1 3476
45
Saxagliptin Approved Phase 3 361442-04-8 11243969
46
Acarbose Approved, Investigational Phase 3 56180-94-0 441184
47
Calcium carbonate Approved, Investigational Phase 3 471-34-1
48
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
49
Mannitol Approved, Investigational Phase 3 69-65-8 453 6251
50
Ethanol Approved Phase 3 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 240)
# Name Status NCT ID Phase Drugs
1 Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Children Growth Hormone Deficiency: A Multicenter, Randomized, Parallel, Dose-control Clinical Trial II Unknown status NCT02908958 Phase 4
2 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Open-label, Phase IV Clinical Trial With Different Administration Dosage of PEG Somatropin Unknown status NCT03249480 Phase 4
3 Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Randomized, Open-label, Parallel Phase IV Clinical Trial With Different Administration Frequency of PEG Somatropin Unknown status NCT02976675 Phase 4
4 Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD) Completed NCT01806298 Phase 4 Saizen® solution for injection (referred as Saizen®)
5 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia Completed NCT00140413 Phase 4 Nutropin AQ
6 The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia Completed NCT02192450 Phase 4 Insulin aspart/glargine;Insulin aspart/degludec
7 Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. Recruiting NCT03491696 Phase 4 Metyrapone
8 Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism Active, not recruiting NCT01848171 Phase 4 L-thyroxine
9 The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study Active, not recruiting NCT01831869 Phase 4 L-thyroxine
10 The EMMED-HF Study: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure Not yet recruiting NCT04071626 Phase 4 Ertugliflozin 5 mg;Placebo oral tablet
11 Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency Terminated NCT01698944 Phase 4 somatropin
12 Placebo Controlled Trial on the Efficacy of Growth Hormone Replacement Therapy in Patients With Growth Hormone Deficiency After Traumatic Brain Injury. Terminated NCT00555009 Phase 4 Genotropin;Placebo
13 Head Trauma With Traumatic Brain Injury (TBI): A Multicenter, Phase IV Study to Evaluate the Effects of Genotropin in Adult Patients With Growth Hormone Deficiency (GHD) Caused by Trauma and/or Head Injury Terminated NCT00638053 Phase 4
14 Randomized Controlled Trial Comparing the Metabolic Efficiency of Allogeneic Pancreatic Islet Transplantation to Intensive Insulin Therapy for the Treatment of Type 1 Diabetes Unknown status NCT01148680 Phase 3
15 Evolution Of Growth Rate In Children Suffering From A Disease Associated With Growth Retardation and Treated By Genotonorm. A Pilot Study. Completed NCT00163215 Phase 3 Somatropin
16 Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency Completed NCT00191360 Phase 3 Somatropin
17 Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency Completed NCT02693522 Phase 3 somatropin;Eutropin
18 Effect of Growth Hormone in Children With Growth Hormone Deficiency and Idiopathic Short Stature Completed NCT00262249 Phase 3 somatropin
19 Investigation of the Efficacy and Safety of NN-220 for 48 Weeks in Adults With Growth Hormone Deficiency Completed NCT00184743 Phase 3 somatropin
20 Effect of Two Years of Treatment With Norditropin® SimpleXx® on Bone Mineral Density in Young Adults With Childhood-Onset Growth Hormone Deficiency Completed NCT00184678 Phase 3 somatropin
21 A Phase III, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency. Completed NCT00294619 Phase 3 growth hormone
22 Investigation of the Efficacy and Safety of NN-220 for 24 Weeks in Adults With Growth Hormone Deficiency Completed NCT00519558 Phase 3 somatropin
23 fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD Completed NCT03305016 Phase 3 TransCon hGH
24 A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency Completed NCT03075644 Phase 3 somapacitan;Norditropin
25 Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men Completed NCT02081300 Phase 3 Oral testosterone undecanoate, LPCN 1021;Topical testosterone gel 1.62 %
26 Norditropin® and Norditropin® Cartridges: An Open-Label, Randomized, Comparative Safety and Efficacy Trial in Children With Growth Hormone Deficiency Completed NCT01502124 Phase 3 somatropin;somatropin
27 A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00736879 Phase 3 Dapagliflozin;Placebo
28 Efficacy and Safety of a High Dosage Compared to the Label Dosage of Humatrope in Early Pubertal Stage Children With Growth Hormone Deficiency Completed NCT00191165 Phase 3 Somatropin;Somatropin
29 A Phase III, Open-label, Uncontrolled, Multicentre, Rollover Study to Assess Safety and Efficacy of LB03002 Administered Weekly in Adults With Growth Hormone Deficiency Completed NCT00596037 Phase 3 Growth hormone - LB03002
30 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone Completed NCT00528879 Phase 3 Dapagliflozin;Placebo;Metformin
31 A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period Completed NCT02229851 Phase 3 somapacitan;somatropin;placebo
32 Pegylated Somatropin in the Treatment of Children With Growth Hormone Deficient:A Multicenter, Randomized, Open-label, Controlled Phase Ⅲ Clinical Trial Completed NCT01495468 Phase 3
33 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT01841697 Phase 3 Omarigliptin;Sitagliptin;Placebo to omarigliptin;Placebo to Sitagliptin;Open-label Metformin;Open-label Glimepiride
34 A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency Completed NCT02382939 Phase 3 somapacitan;somatropin
35 A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control Completed NCT02273050 Phase 3 Saxagliptin 5 mg;Placebo 5 mg for Saxagliptin;Placebo 500 mg for metformin (with titration);Metformin 500 mg with titration
36 A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00859898 Phase 3 Dapagliflozin;Metformin XR;Metformin XR;dapagliflozin matching Placebo;metformin HCl Modified Release matching Placebo
37 A Randomised, Open-label, Parallel-group, Multi-centre Trial to Compare the Efficacy and Safety for 12 Months of Zomacton to Genotropin in Children With Idiopathic Growth Hormone Deficiency Completed NCT00884000 Phase 3 Genotropin;Zomacton
38 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) Completed NCT01137474 Phase 3 Dapagliflozin;Placebo-matching dapagliflozin
39 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication Completed NCT01195662 Phase 3 Dapagliflozin;Placebo matching Dapagliflozin
40 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Completed NCT01814748 Phase 3 Omarigliptin;Placebo to omarigliptin;Metformin
41 A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD) Completed NCT02781727 Phase 3 Once weekly subcutaneous injection of TransCon hGH;Once daily subcutaneous injection of Genotropin
42 A Phase III, Multicentric, Open-label, Randomised, Comparative, Parallel Group Study of (GHRH + Arginine) Combination Test vs. Insulin Tolerance Test (ITT) in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) Completed NCT01060488 Phase 3
43 Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT) Completed NCT02558829 Phase 3 Macimorelin;Insulin
44 A Phase IIIb, Prospective, Multicenter, Randomized, Open-label Study to Determine the Safety and Efficacy of Two Different Dosing Regimens of Saizen® (Recombinant Human Growth Hormone (r-hGH), Using Cool.Click™ in Subjects With Childhood-onset Growth Hormone Deficiency During the Adolescent Transition Phase (CATS) Completed NCT00109733 Phase 3
45 Efficacy and Safety of CinnaGen Recombinant Human Growth Hormone (CinnaTropin®) in Comparison With Novo Nordisk Growth Hormone (Nordilet®) Product in Pre-Pubertal Children With Idiopathic Growth Hormone Deficiency (IGHD) Completed NCT03223025 Phase 3 CinnaTropin®;Nordilet®
46 A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin Completed NCT02104804 Phase 3 Saxagliptin 5mg;Placebo for Saxagliptin
47 Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4) Recruiting NCT03730662 Phase 3 Tirzepatide;Insulin Glargine
48 enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial Recruiting NCT03344458 Phase 3 TransCon hGH
49 A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Active, not recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
50 A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma Active, not recruiting NCT01964430 Phase 3 nab-Paclitaxel 125 mg/m2;gemcitabine 1000 mg/m2;gemcitabine 1000 mg/m2

Search NIH Clinical Center for Endocrine System Disease

Cochrane evidence based reviews: endocrine system diseases

Genetic Tests for Endocrine System Disease

Genetic tests related to Endocrine System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Endocrine System 29
2 Disorder of Endocrine System 29

Anatomical Context for Endocrine System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Endocrine System Disease:

19
Endocrine Glands Which Secretes A Type Of Hormone Directly Into The Bloodstream To Regulate The Body

MalaCards organs/tissues related to Endocrine System Disease:

40
Bone, Testes, Heart, Thyroid, Brain, Lung, Liver

Publications for Endocrine System Disease

Articles related to Endocrine System Disease:

(show all 30)
# Title Authors PMID Year
1
Molecular mechanisms underlying zinc oxide nanoparticle induced insulin resistance in mice. 61
31519126 2020
2
Parameters Related to Lumbar Puncture Do not Affect Occurrence of Postdural Puncture Headache but Might Influence Its Clinical Phenotype. 61
31562971 2020
3
Ramadan and Health. Bibliometric study of the biomedical literature indexed in «Medline» database. 61
31691944 2019
4
Characteristics of olfactory ensheathing cells and microarray analysis in Tupaia belangeri (Wagner, 1841). 61
31257532 2019
5
The anti-hyperglycemia effects of Rhizoma Coptidis alkaloids: A systematic review of modern pharmacological studies of the traditional herbal medicine. 61
30836124 2019
6
An ultrasensitive sensor based on quantitatively modified upconversion particles for trace bisphenol A detection. 61
30390111 2019
7
[Effect of anthropo-technogenic load on medico-social aspects of primary morbidity and disability of population.] 61
30607922 2018
8
Evaluation of the carcinogenic risks at the influence of POPs. 61
28854146 2017
9
Medical comorbidities in children and adolescents with autism spectrum disorders and attention deficit hyperactivity disorders: a systematic review. 61
28674760 2017
10
Analysis on nutritional risk screening and influencing factors of hospitalized patients in central urban area. 61
28786068 2017
11
[Peculiarities of disorders in physical development of children consuming drinking water with increased nitrate content]. 61
30645861 2017
12
Influence of PCOS in Obese vs. Non-Obese women from Mesenchymal Progenitors Stem Cells and Other Endometrial Cells: An in silico biomarker discovery. 61
28539732 2017
13
Binge-eating disorder in the Swedish national registers: Somatic comorbidity. 61
27642179 2017
14
[Study on skeletal muscle mass of 1 836 check-up adults and its association with age in Qiqihar]. 61
26957241 2016
15
[Features of physical development of girls residing in the altai territory with the different level of the environmental load]. 61
29424996 2016
16
[Clinical analysis for systemic complications of patients in the dental emergency room]. 61
25882958 2015
17
[Etiologies and clinical features of 19 cases with bilateral acute sensorineural hearing loss]. 61
25764919 2015
18
[High-tech medical care in surgical endocrinology]. 61
25146543 2014
19
[The role of selenium in endocrine system diseases]. 61
24095912 2013
20
[The structure of emergency calls of the intensive care team depending on age and gender of patients appealed for urgent medical aid]. 61
22168066 2011
21
[Working despite having diseases: Endocrine system diseases and metabolic diseases]. 61
21584990 2010
22
[Etiological analysis and individualized treatment of pharyngeal paraesthesia]. 61
19894556 2009
23
[Endocrinal dysfunctions in liver failure of different etiologies and during interferon therapy in patients with chronic hepatitis B and C]. 61
18634398 2008
24
[The potential dangers of endocrinal disorders]. 61
11852452 2002
25
[Coenzyme Q--clinical significance]. 61
8999700 1994
26
Increased deaths due to endocrine system diseases and allergies among mothers of dizygotic twins. 61
6538639 1984
27
[Dental treatment in patients with endocrine system diseases]. 61
6458900 1981
28
[Compensation of the hormonal and metabolic disorders as a general principle in treating endocrine system diseases]. 61
6892937 1980
29
[Acute crisis in endocrine system diseases]. 61
4572045 1973
30
[Endocrine system diseases and estrogen]. 61
18860221 1947

Variations for Endocrine System Disease

Expression for Endocrine System Disease

Search GEO for disease gene expression data for Endocrine System Disease.

Pathways for Endocrine System Disease

Pathways related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.99 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
2 10.71 MIR9-1 MIR221 MIR199A1
3 10.27 MIR199A1 MIR145

GO Terms for Endocrine System Disease

Cellular components related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 SERPINA3 MIR30A MIR221 MIR21 MIR199A1 MIR17

Biological processes related to Endocrine System Disease according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.04 MIR34A MIR30A MIR21 MIR155 MIR125A
2 negative regulation of gene expression GO:0010629 9.93 MIR214 MIR21 MIR17 MIR155 MIR125A
3 positive regulation of protein kinase B signaling GO:0051897 9.91 MIR221 MIR21 MIR199A1 MIR126
4 positive regulation of angiogenesis GO:0045766 9.9 MIR30A MIR21 MIR199A1 MIR126
5 negative regulation of cell migration GO:0030336 9.89 MIR9-1 MIR34A MIR214 MIR21
6 positive regulation of inflammatory response GO:0050729 9.83 MIR21 MIR155 MIR126
7 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.78 MIR30A MIR221 MIR214
8 cellular response to hypoxia GO:0071456 9.77 MIR34A MIR214 MIR17 MIR155 MIR126
9 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.76 MIR221 MIR214 MIR21 MIR17
10 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.75 MIR21 MIR199A1 MIR145
11 negative regulation of sprouting angiogenesis GO:1903671 9.74 MIR34A MIR221 MIR17
12 positive regulation of blood vessel endothelial cell migration GO:0043536 9.73 MIR30A MIR221 MIR200A MIR126
13 negative regulation of angiogenesis GO:0016525 9.72 MIR34A MIR214 MIR21 MIR145 MIR125A
14 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.71 MIR483 MIR221 MIR196A1 MIR155
15 positive regulation of sprouting angiogenesis GO:1903672 9.7 MIR155 MIR126 MIR125A
16 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.69 MIR34A MIR214 MIR21
17 negative regulation of JAK-STAT cascade GO:0046426 9.67 MIR9-1 MIR155
18 negative regulation of necroptotic process GO:0060546 9.67 MIR221 MIR214 MIR155
19 negative regulation of innate immune response GO:0045824 9.66 MIR21 MIR155
20 negative regulation of hydrogen peroxide-induced cell death GO:1903206 9.66 MIR17 MIR155
21 positive regulation of microglial cell activation GO:1903980 9.65 MIR155 MIR142
22 positive regulation of metalloendopeptidase activity GO:1904685 9.65 MIR21 MIR17
23 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.65 MIR199A1 MIR17 MIR155
24 negative regulation by host of viral genome replication GO:0044828 9.64 MIR221 MIR155
25 negative regulation of regulatory T cell differentiation GO:0045590 9.63 MIR21 MIR155
26 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.63 MIR21 MIR17
27 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.62 MIR221 MIR155
28 negative regulation of lamellipodium assembly GO:0010593 9.62 MIR214 MIR196A1
29 negative regulation of cell adhesion molecule production GO:0060354 9.58 MIR221 MIR155
30 positive regulation of vascular smooth muscle cell dedifferentiation GO:1905176 9.56 MIR221 MIR214
31 positive regulation of connective tissue replacement GO:1905205 9.56 MIR34A MIR214 MIR199A1 MIR155
32 miRNA mediated inhibition of translation GO:0035278 9.56 MIR9-1 MIR483 MIR30A MIR221 MIR21 MIR17
33 negative regulation of vascular wound healing GO:0061044 9.55 MIR34A MIR155
34 gene silencing by miRNA GO:0035195 9.5 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
35 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.46 MIR214 MIR199A1 MIR17 MIR155

Molecular functions related to Endocrine System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.5 MIR9-1 MIR483 MIR34A MIR30A MIR221 MIR214
2 RNA polymerase II complex binding GO:0000993 9.13 MIR145 MIR126 MIR125A

Sources for Endocrine System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....